Molecular genetics of prostate cancer.
- 1 January 2001
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 33 (2) , 130-141
- https://doi.org/10.3109/07853890109002068
Abstract
The molecular mechanisms underlying the development and progression of prostate cancer are poorly understood. Epidemiological studies have suggested that 5-10% of all prostate cancers are familial, and numerous chromosomal loci have been associated with prostate cancer in multicentre linkage studies. However, no putative susceptibility genes harboured in these chromosomal regions have thus far been identified. Several recurrent chromosomal alterations in prostate cancer have been detected in comparative genomic hybridization (CGH) and loss of heterozygosity (LOH) analysis. The target genes for many of these aberrations are still not known. It seems that the androgen receptor (AR) signalling pathway plays a crucial role in both early development as well as in late progression of the disease. Both germ-line and somatic genetic alterations in the AR gene have been demonstrated in prostate cancer patients. The intention of this review is to summarize the current knowledge of molecular mechanisms in the development of prostate cancer.Keywords
This publication has 98 references indexed in Scilit:
- A Genome Screen of Multiplex Sibships with Prostate CancerAmerican Journal of Human Genetics, 2000
- Androgen receptor gene mutations in hormone-refractory prostate cancerThe Journal of Pathology, 1999
- p53 MUTATIONS IN PROSTATE CANCER BONE METASTASES SUGGEST THAT SELECTED p53 MUTANTS IN THE PRIMARY SITE DEFINE FOCI WITH METASTATIC POTENTIALJournal of Urology, 1999
- Genetic Alterations in Hormone-Refractory Recurrent Prostate CarcinomasThe American Journal of Pathology, 1998
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancersGenes, Chromosomes and Cancer, 1996
- Point Mutations of the Mxil Gene are Rare in Prostate CancersThe Prostate, 1996
- Mutation of the MXI1 gene in prostate cancerNature Genetics, 1995
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990